Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Frazier Life Sciences Public Fund, L.P.

2. Date of Event Requiring Statement (MM/DD/YYYY) 8/16/2021

3. Issuer Name and Ticker or Trading Symbol

Viridian Therapeutics, Inc.DE [VRDN]

(Last) (First) (Middle)

C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director ___X___ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Street)

SEATTLE, WA 98101

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1305200 ⁽¹⁾	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

(1)

These shares are held directly by Frazier Life Sciences Public Fund L.P. The general partner of Frazier Life Sciences Public Fund L.P. is FHMLSP, L.P. and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Frazier Life Sciences Public Fund L.P. FHMLSP, L.P. and FHMLSP, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by Frazier Life Sciences Public Fund L.P., except to the extent of its pecuniary interest therein, if any.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Frazier Life Sciences Public Fund, L.P. C/O FRAZIER HEALTHCARE PARTNERS 601 UNION STREET, SUITE 3200 SEATTLE, WA 98101		X
FHMLSP, L.L.C. C/O FRAZIER HEALTHCARE PARTNERS 601 UNION STREET, SUITE 3200 SEATTLE, WA 98101		X
FHMLSP, L.P. C/O FRAZIER HEALTHCARE PARTNERS 601 UNION STREET, SUITE 3200 SEATTLE, WA 98101		X

Signatures
Frazier Life Sciences Public Fund L.P., By: FHMLSP, L.P., its General Partner. By: FHMLSP, L.L.C., its General Partner, By: /s/ Steve R. Bailey, Chief Financial Officer		8/26/2021
^**Signature of Reporting Person		Date
FHMLSP, L.L.C., By: /s/ Steve R. Bailey, Chief Financial Officer		8/26/2021
^**Signature of Reporting Person		Date
FHMLSP, L.P., By: FHMLSP, L.L.C., its General Partner, By: /s/ Steve R. Bailey, Chief Financial Officer		8/26/2021
^**Signature of Reporting Person		Date